Status and phase
Conditions
Treatments
About
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with Comirnaty.
Full description
Approximately 400 participants aged ≥18 years old and previously vaccinated with 2 or 3 doses of Comirnaty will be enrolled in this study. They will be randomly assigned to SCTV01E Group and Comirnaty Group in a ratio of 1:1.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants are eligible to be included in the study only if the following conditions are met:
Exclusion criteria
A participant who conforms to any of the following criteria should be excluded from the study:
Primary purpose
Allocation
Interventional model
Masking
400 participants in 2 patient groups
Loading...
Central trial contact
Dilihumare ·Niyazi
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal